{"prompt": "['Novartis', 'Confidential', 'Page 45', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'All patients who are entered into the run-in period of the study will additionally have all', 'adverse events occurring after informed consent is signed recorded on the AE page and have', 'the run-in disposition page for run-in period collected.', '6.2 Patient demographics/other baseline characteristics', 'Patient demographic and baseline characteristic data to be collected on all patients include:', 'Date of birth (where allowed by local legislation)', 'Age (calculated)', 'Sex', 'Race and ethnicity', 'Patients initials (where allowed by local legislation)', 'Height and Weight', 'BMI (calculated)', 'Baseline physical examination (not databases other than in the context of relevant medical', 'history)', 'Vital signs', 'ECG', 'Date of diagnosis of asthma', 'Relevant medical history/ current medical condition present before signing the informed', 'consent', 'Smoking history and status', 'Asthma Quality of Life (AQLQ)', 'Asthma Control (ACQ-7)', 'Prior concomitant medication (Both asthma related and non-asthma related)', 'Pre and post-bronchodilator spirometry (run-in spirometry and reversibility testing)', '6.3 Treatment exposure and compliance', 'Study treatment compliance should be assessed by the investigator and/or site personnel at all', 'visits. Where necessary, the Investigator will discuss compliance issues with the patient.', '6.4 Efficacy', 'The following assessments of efficacy will be performed:', 'Health Status (PROs: AQLQ, ACQ-7,', ')', 'Spirometry']['Novartis', 'Confidential', 'Page 46', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '6.4.1 Health Status (Patient Reported Outcomes)', \"A patient- reported outcome (PRO) is any report of the status of a patient's health condition\", \"that comes directly from the patient, without interpretation of the patient's response by a\", 'clinician or anyone else.', 'Patient-reported outcomes may provide quantitative information for patients regarding the', \"'impact on daily life', which is of key importance, for patients and their physicians and also\", 'for health technology assessments.', 'In this study, the main efficacy variable is a PRO to assess the impact of uncontrolled asthma', \"and the disease's management beyond lung function. All PROs should always be completed\", 'before any other assessments are performed to avoid influencing the responses. When', 'occurring at the same visit they are to be completed in the following order: AQLQ-S, ACQ-7,', '6.4.1.1 Asthma Quality of Life Questionnaire (AQLQ-S)', 'The AQLQ is a 32-item asthma specific questionnaire designed to measure functional', 'impairments that are most important to patients with asthma (Appendix 7). It consists of 4', 'domains: symptoms, emotions, exposure to environmental stimuli and activity limitation.', 'Patients are asked to recall their experiences during the previous 2 weeks and to score each', 'item on a 7-point scale (Juniper 1992, Juniper 1993). The overall AQLQ score is the mean', 'response to all 32 questions. Clinically important differences in scores between any two', 'assessments have been determined by the authors of the AQLQ. Changes in scores of 0.5 are', 'considered clinically meaningful; changes of 1.0 are considered as moderate and > 1.5 as', 'large changes for any individual domain or for the overall summary score (Juniper 1994).', 'AQLQ should be completed by the patient (self-administered) at the clinic as per Assessment', 'Schedule Table 6-1.', '6.4.1.2 Asthma Control Questionnaire (ACQ-7)', 'In this study, the ACQ-7 (Appendix8) will be used to assess improvements in asthma', 'symptom control. The ACQ-7 (Juniper 1999; Juniper 2005; Juniper 2006) is a seven-item', 'disease-specific instrument developed and validated to assess asthma control in patients in', 'clinical trials as well as in individuals in clinical practice. The ACQ-7 questionnaire will be', 'provided to the site. The ACQ-7 questionnaire consists of five items to assess symptoms and', 'activity limitations, one question to assess rescue medication use, and one question to assess', 'airway caliber (FEV1% predicted). All seven items are scored on a 7-point Likert scale, with 0', 'indicating total control and 6 indicating poor control. The questions are equally weighted and', 'the total score is the mean of the seven items. The proportion of patients who achieve an', 'improvement of at least 0.5 in ACQ-7 (i.e. decrease of ACQ-7 score of at least 0.5 from', 'baseline) at post-baseline visits will also be analyzed.', 'The first 6 questions of the ACQ-7 should be completed by the patient based on one recall', 'over the prior week. The last question should be completed by the investigator at the site', 'using data from the spirometer. The ACQ-7 should be completed at the clinic as per', 'Assessment Schedule Table 6-1.']\n\n###\n\n", "completion": "END"}